Načítá se...
Targets for Ibrutinib Beyond B Cell Malignancies
Ibrutinib (Imbruvica(™)) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat. Few, if any medicin...
Uloženo v:
| Vydáno v: | Scand J Immunol |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5347933/ https://ncbi.nlm.nih.gov/pubmed/26111359 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/sji.12333 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|